Diligence memo · auto-generated · as of July 2, 2026
Aquinox Pharmaceuticals (Usa) Inc
Aquinox Pharmaceuticals (Usa) Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Aquinox Pharmaceuticals (Usa) Inc operates in Pharmaceuticals, based in RICHMOND.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aquinox Pharmaceuticals (Usa) Inc has raised $31M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $14M on 2013-03-19.
Most recent recorded round closed around 2013-03-19.
Valuation (modeled)modeled
Provath models Aquinox Pharmaceuticals (Usa) Inc at approximately $434M (range $16M–$2.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.21× the median modeled value of Series A Pharmaceuticals companies in 2013–2015 (64 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 13.3 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 74% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 79% of those peers.
Closest niche peers: Neurovia, Inc., Romark Global Pharma, LLC, Access Pharmaceuticals Inc, Minnesota Medical Solutions LLC, OncoQuest Inc..
Peoplefiled
20 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.